Neuraly, a biotech company founded on technology created at the Johns Hopkins School of Medicine, is focused on the development of neuroprotective agents for neurologic disorders such as Alzheimer's disease and Parkinson's disease. In addition to NLY01, Neuraly's growing pipeline includes two candidates in early development targeting complementary mechanisms of neurodegenerative diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/18/18 | $36,000,000 | Series A |
D&D Pharmatech Dongkoo Bio&Pharma Geon Investment InterVest LB Investment Magna Investment Maryland Venture Fund Octave Life Sciences Smilegate Investment | undisclosed |
